Epizyme Files for IPO of Up to $69 Million
4/19/2013 7:57:51 AM
Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company recently entered into a collaboration agreement with Abbott Laboratories to develop a diagnostic to detect which patients would qualify for Epizyme's product candidates. The Cambridge, MA-based company, which was founded in 2007 and booked $45 million in collaboration revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol EPZM.